ARCHIVES

MGI Pharma, MethylGene Begin Phase II Trial Of MG98.

This article is from The Cancer Letter archive.

Vol. 27 No. 35 | September 28, 2001

Download PDF Visit The Full Archive

Related Articles

Research Program For Biological Response Modifiers Outlined By DCT board Subcommittee

November 16, 1979

Also Kevin Cullen named director, Univ. of Maryland Greenebaum Cancer Center.

November 28, 2003

Advisors Ok New RFP For Natural Product Large-Scale Production

March 6, 1992

Funding Opportunities.

May 3, 2002

Bach: LCA Center Certification Untrustworthy; CISNET Models Don’t Match

May 9, 2014

New CIDAC RFP Limits Recompetition To Small Business Firms

January 6, 1984